Trial Profile
A study evaluating safety and efficacy of switching to rilpivirine from first-line regimens in virologically suppressed patients living in an Asian resource-limited setting.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Aug 2017
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 31 Aug 2017 New trial record
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science